US Patent Issued to Novartis on Dec. 16 for "Compounds targeting PMP22 for the treatment of Charcot-Marie-Tooth disease" (California Inventors)

ALEXANDRIA, Va., Dec. 16 -- United States Patent no. 12,497,616, issued on Dec. 16, was assigned to Novartis AG (Basel, Switzerland).

"Compounds targeting PMP22 for the treatment of Charcot-Marie-Tooth disease" was invented by Charles Allerson (San Diego) and Arthur T. Suckow (San Diego).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are compounds for inhibiting peripheral myelin protein 22 (PMP22) mRNA. Also provided herein are methods of using such compounds for the treatment of Charcot-Marie-Tooth disease."

The patent was filed on May 10, 2024, under Application No. 18/660,600.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-...